Dr. Massey is a world-renowned neuropharmacologist, pharmacogeneticist, life sciences professional, inventor and entrepreneur. Dr. Massey received his Ph.D. in Pharmacology at the University of Arkansas for Medical Sciences and subsequently an investigator at the Pritzker School of Medicine’s Drug Abuse Research Center at The University of Chicago. Dr. Massey holds a long-standing adjunct faculty appointment at the University of Arkansas for Medical Sciences (Associate Professor, Dept. of Pharmacology and Interdisciplinary Toxicology).
Dr. Massey has held leadership positions at Merck, Astra Merck, Quintiles, Scirex, Astra Zeneca, Scientific Commercialization, Litmus Molecular Design, SureGene, and GeneAlign. He has played a leadership role in placing 28 new drugs into human testing and 8 new drugs onto the market. Dr. Massey formerly held the Jack Martin, MD Research Professorship in Psychopharmacology at Vanderbilt University, where he conducted research into the genetics, biological basis and pharmacological treatment of schizophrenia and serious mental illness. He continued the work in schizophrenia as a Visiting Scholar in Psychiatry at Northwestern University’s Feinberg School of Medicine. Dr. Massey is the Co-Founder and Managing Partner of Advanced Therapeutic Applications LLC, a provider of treatment recommendations based on genetics.